- Report
- July 2024
- 120 Pages
Global
From €5223EUR$5,950USD£4,482GBP
- Report
- March 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,382GBP
- Report
- May 2025
- 134 Pages
Global
From €2633EUR$2,999USD£2,259GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2633EUR$3,000USD£2,260GBP
- Report
- April 2025
- 200 Pages
Global
From €6979EUR$7,950USD£5,988GBP
- Drug Pipelines
- April 2025
- 100 Pages
Global
From €2633EUR$3,000USD£2,260GBP
- Report
- August 2022
- 222 Pages
Global
From €3072EUR$3,500USD£2,636GBP
- Report
- May 2024
- 139 Pages
Global
From €5705EUR$6,499USD£4,895GBP
Ozanimod is a drug used to treat immune disorders, such as multiple sclerosis (MS) and ulcerative colitis (UC). It is an oral, selective sphingosine 1-phosphate (S1P) receptor modulator that works by modulating the immune system. Ozanimod is believed to reduce the number of relapses in MS patients and reduce the symptoms of UC. It is also being studied for its potential to treat other immune-mediated diseases, such as Crohn's disease and psoriasis.
Ozanimod is currently approved for use in the United States, Canada, and the European Union. It is also being studied in clinical trials for its potential to treat other immune-mediated diseases.
Companies in the Ozanimod market include Celgene Corporation, Receptos, Inc., and Novartis AG. Show Less Read more
